Paramount Biosciences

Paramount Biosciences invests exclusively in early-stage biotechnology and pharmaceutical companies developing novel human therapeutics. The firm concentrates on preclinical and Phase I/II assets, prioritizing scientific risk evaluation over commercial-stage deal-making. This single-sector mandate distinguishes it from healthcare generalists that also allocate to services, devices, or health IT.

The firm typically deploys capital through direct equity stakes, convertible notes, and royalty-based financing agreements. Deal sizes are estimated to range from $2 million to $15 million, depending on the asset's scientific maturity and capital requirements. Paramount may also participate in forming new companies around in-licensed intellectual property.

Paramount's investment decisions are led by managing partners with significant pharmaceutical industry and academic research backgrounds. The team includes principals holding MD or PhD credentials who conduct primary scientific due diligence rather than relying solely on external advisors. Specific named principals have not been widely disclosed in public materials.

Paramount has historically maintained a footprint in oncology, rare genetic diseases, and central nervous system disorders. The firm evaluates platform technologies and single-asset opportunities where biological mechanisms are well-validated but commercial pathways remain undefined. Public disclosures do not specify a comprehensive exclusion list by therapeutic area.

Paramount deliberately avoids healthcare services, medical devices, diagnostics, and revenue-stage pharmaceutical companies. By restricting its mandate to preclinical and early-clinical therapeutic R&D, the firm takes on concentrated binary risk — a structural choice that sets it apart from multi-asset healthcare platforms common in the New York market.